FDA approval of a new medical device, especially one that treats a condition like tricuspid regurgitation, is a significant positive development for the company. It not only opens up a new revenue stream but also strengthens Edwards Lifesciences' position in the market for heart valve therapies. Given the importance of regulatory approvals in the healthcare sector, this news is likely to be viewed positively by investors and could lead to a short-term increase in the company's stock price.